Drugs / RLD2001-1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05199129 | Nov 2021 → Sep 2022 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07660796 Comparator | Jul 2026 → Oct 2027 expected | essential hypertension | Hanmi Pharmaceutical Company Limited | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06438172 Comparator | Mar → Dec 2024 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT04820907 Comparator | Oct 2020 → Sep 2021 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2001-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660796 ↗ |
| Route | Oral | “orally” NCT04820907 ↗ |